sensitivity was associated with a significant decrease in fatty acid oxidation rates in the BCATm^{-/-} failing hearts compared to the WTCre^{+/+} failing hearts. This decrease in fatty acid oxidation in the BCATm^{-/-} failing hearts was associated with a significant decrease in myocardial oxygen consumption rates. As a result, cardiac efficiency (cardiac work/myocardial oxygen consumption) was significantly increased in the BCATm^{-/-} failing hearts compared to the WTCre^{+/+} failing hearts.

Conclusions/implications We conclude that the accumulation of BCKA, and not BCAA, is a major contributor to cardiac insulin resistance via abrogating mitochondrial translocation of Akt. Targeting BCKA may represent a potential therapeutic approach to improve cardiac insulin-stimulated glucose oxidation in the setting of heart failure, obesity and diabetes.

Conflict of Interest None

BS33 THE RAF 'PARADOX BREAKER' INHIBITOR, PLX8394, ACTIVATES ERK1/2 IN ENDOTHELIAL CELLS AND PROMOTES CARDIAC REMODELLING

¹Susanna Cooper, ²Josh Cull, ²Angela Clerk, ¹Daniel Meijles. ¹St. George's University of London, London, UK; ²University of Reading, UK

10.1136/heartjnl-2021-BCS.231

Introduction RAF kinases activate the ERK1/2 cascade, a key pathway involved in cardiac remodelling and cytoprotection. Since activating mutations in BRAF cause cancer, small molecule inhibitors of RAF have been developed. However, a paradoxical effect is observed with some inhibitors which activate rather than inhibit ERK1/2. Therefore, 'paradox breaker' inhibitors have been developed as new-generation cancer therapies void of this effect (e.g. PLX8394). Here, we determined the effects of PLX8394 on endothelial cell (EC) ERK1/2 signalling and the heart in vivo.

Methods Murine ECs were incubated with PLX8394 and effects on ERK1/2 activity determined by western blotting for the phosphorylated (i.e. activated) kinases. Effects on gene expression were determined by qPCR. The effects of PLX8394 on the heart in vivo were determined by infusing male wildtype C57Bl/6J mice (10-12wks, n= 6/group) with PLX8394 (5mg/kg/d, 7d) using osmotic minipumps. Cardiac function/dimensions were assessed using echocardiography; effects on cardiac morphology were assessed by histological staining. mRNA expression was assessed by qPCR. Statistical tests used 1-way ANOVA with Holm-Sidak's post-test (in vitro studies) and unpaired t-tests (in vivo studies).

Results PLX8394 activated ERK1/2 in ECs in a time (7.4 ±2.3-fold at 5 min; p=0.0365; n=5) and concentration (>1μM; p=0.0625; n=3) dependent manner. This was associated with significant increases in expression of mRNAs encoding the immediate early gene Fos (6.1±2.6-fold; p<0.0001; n=4) and the vasoconstrictor peptide endothelin-1 (Edn1) (2.7±0.9-fold; p=0.0038; n=4). In vivo, PLX8394 decreased cardiac output (p=0.0092), predominantly through reduced stroke volume (p=0.0103). Structurally, PLX8394 promoted cardiac hypertrophy, with increased diastolic left ventricular (LV) posterior wall thickness (p=0.0425) and decreased LV internal diameter (p=0.0463) at 7 d. Cardiac hypertrophy resulted from increased cardiomyocyte cross-sectional area (p=0.0002) despite no changes in Myh7, Nppa or Nppb mRNAs. Moreover, PLX8394-induced cardiac

remodelling was not due to increased fibrosis, with no change in mRNA expression of collagens1-4 and using histological assessment.

Conclusion Despite being developed as a 'paradox breaker' for cancer, PLX8394 promoted ERK1/2 signalling in murine ECs and cardiac remodelling in vivo. These preliminary findings suggest that such inhibitors, currently in Phase 3 trials for RAF-mutant cancers, have potential to modulate cardiac function in patients.

Conflict of Interest N/A

BS34 TELOMERE DAMAGE PROMOTES VASCULAR SMOOTH MUSCLE CELL SENEESCENCE AND IMMUNE CELL RECRUITMENT AFTER VESSEL INJURY

¹Mandy Grootaert, ¹Anna Uryga, ¹Abel Garrido, ¹Sebnem Oc, ¹Kirsty Foote, ¹Joel Chappell, ¹Alison Finigan, ²Francesca Rossiello, ²Fabrizio d'Adda di Fagnana, ¹Dimitra Aravani, ¹Helle Jorgensen, ¹Martin Bennett. ¹University of Cambridge, Cambridge, UK; ²FIRC Institute of Molecular Oncology Foundation, IFOM Foundation, Milan

10.1136/heartjnl-2021-BCS.232

Aim Vascular smooth muscle cells (VSMCs) accumulate in injury-induced neointimal lesions and atherosclerotic plaques in an oligoclonal fashion, yet plaque VSMCs show reduced proliferation and cell senescence. DNA damage leads to VSMC senescence and inflammation, and VSMC senescence promotes atherosclerosis; however, the exact mechanism by which VSMC senescence promotes lesion formation is not known. Here, we investigated telomere damage-induced VSMC senescence, the contribution of senescence-induced inflammation and the mechanisms involved, the consequences of VSMC senescence in vivo after injury, and whether it promotes clonality.

Methods Stress-induced premature senescence (SIPS) was induced by the chemotherapeutic doxorubicin (24h treatment + 21d recovery). Lentiviruses were used to stably overexpress a dysfunctional TRF2 mutant protein (TRF2T188A) in human VSMCs (hVSMCs). SM22aTRF2T188A mice were generated that express human TRF2T188A in VSMCs only, and crossed with Myh11-CreERT2 Rosa26-Confetti multicolour reporter mice, to study cell senescence and clonality in vivo. Arterial injury was induced in these mice by ligation of the left common carotid artery for 28 days.

Results Both SIPS and TRF2T188A-induced VSMC senescence were characterised by persistent telomere damage, and associated with formation of micronuclei, activation of cGAS-STING cytoplasmic DNA sensing, and induction of multiple pro-inflammatory cytokines. Silencing of cGAS in TRF2T188A hVSMCs partially inhibited NFκB-dependent cytokine expression. In vivo, VSMC-specific TRF2T188A expression in a multicolour clonal VSMC-tracking model demonstrated no change in VSMC clonal patches after injury, but increased neointima formation (figure 1), outward remodelling and cellular senescence. Moreover, neointimal lesions of VSMC-specific TRF2T188A mice were characterised by increased ICAM1 expression and increased abundance of CD45+, CD3+ and CD68+ cells when compared to littermate controls, indicating increased immune/inflammatory cell infiltration and/or retention.

Conclusions Persistent telomere damage promotes VSMC senescence and inflammation, and exacerbates neointima formation after injury. Our data suggest that persistent telomere damage-induced VSMC senescence plays a major role in

Abstract BS34 Figure 1

driving inflammation through immune cell recruitment in vascular disease. Targeting senescence and senescence-associated inflammation in particular, could limit injury-induced neointima formation and neoatherosclerosis.

Conflict of Interest No

BS35 PONTIN REGULATES CARDIAC REMODELLING BY MODULATING THE HIPPO PATHWAY IN CARDIOMYOCYTES

Bayu Lestari, Thuy Anh Bui, Sukhpal Prehar, Min Zi, Efta Triastuti, Ardiansah Bayu Nugroho, Ryan Potter, Nicholas Stafford, Elizabeth Cartwright, Alicia D'Souza, Delvac Oceandy. *Division of Cardiovascular Sciences, FBMH, University of Manchester, Manchester, UK*

10.1136/heartjnl-2021-BCS.233

The development of heart failure (HF) is characterised by adverse remodelling events such as hypertrophy, fibrosis, and apoptosis, which together can alter the size, shape, and function of the heart. Identification of new factors that are involved in these processes is important in developing new strategies for HF therapy. Pontin (RUVBL1) is a member of the AAA+ protein family that regulates embryonic zebrafish heart development; however, its role in the adult mammalian heart is unknown. Our previous studies have found that Pontin can induce the activity of the major downstream effector of the Hippo pathway YAP, which is known to play an essential role in mediating cardiac remodelling. Thus, in this study, we aim to investigate the roles of Pontin in mediating adverse cardiac remodelling.

Pontin knock-down (KD) and overexpression (OE) in primary neonatal rat cardiomyocytes (NRCM) were achieved by siRNA-mediated gene silencing and adenoviral-mediated overexpression, respectively. We found that Pontin KD negatively modulates NRCM proliferation, represented by a significant reduction in Ki67-positive cells and EdU-incorporation compared to control. Moreover, Pontin KD significantly reduces the level of active YAP, nuclear YAP localisation, and YAP transcriptional activity in NRCM. In contrast, Pontin OE induced NRCM

proliferation by approximately 1.6 folds as determined by Ki67 staining and EdU incorporation assay. YAP activity and nuclear translocation were also significantly increased following Pontin OE. We also found that Pontin OE reduced cardiomyocyte hypertrophy and apoptosis (TUNEL staining) in response to Angiotensin II stimulation, whereas KD of Pontin increased Angiotensin-stimulated hypertrophy and apoptosis.

To study the role of Pontin in vivo, we generated a mouse model with an inducible cardiomyocyte-specific knockout of Pontin (Pontin^{Cre} KO) by crossing Pontin^{flox/flox} mice with α MHC-MerCreMer transgenic mice. Induction of Pontin ablation was achieved by intraperitoneal injection with tamoxifen. We found that Pontin^{Cre} KO mice exhibited a severe cardiomyopathy phenotype at four weeks after tamoxifen injection, which was characterised by a significant reduction of ejection fraction, increased cardiac fibrosis and hypertrophy, and profound cardiomyocyte apoptosis.

In conclusion, our study has identified Pontin as a key regulator of cardiac remodelling, likely by modulating the Hippo pathway. Further studies are needed to explore the therapeutic potentials of Pontin in controlling cardiac remodelling.

Conflict of Interest None

BS36 SELECTIVE ACTIVATION OF PRIMED VASCULAR SMOOTH MUSCLE CELLS

Jordi Lambert, Sebnem Oc. *Cambridge university, Cambridge, UK*

10.1136/heartjnl-2021-BCS.234

Dysregulation of vascular smooth muscle cells (VSMCs) is a hallmark of vascular diseases including aneurysm and atherosclerosis. VSMCs in healthy vessels maintain a contractile and quiescent phenotype, but can be 'activated' and undergo phenotypic switching to a synthetic, proliferative state when under stress. Previously, we have shown that VSMC expansion after carotid ligation and in atherosclerotic lesions is oligoclonal, meaning activation is restricted to few VSMCs (Chappell et al., 2016, PMID: 27682618). Further to this, we identified a small population of Sca1+ VSMCs with reduced expression of contractile markers in healthy vasculature (Dobnikar et al., 2018, PMID: 30385745), which we hypothesize may have increased responsiveness. However, the mechanisms behind selective VSMC activation and the relevance of Sca1+ cells in disease are yet to be elucidated.

To investigate VSMC activation dynamics, we used a murine carotid ligation injury model, which acutely induces VSMC proliferation. We conducted single-cell RNA-sequencing (scRNA-seq) 5 days after injury, corresponding with the onset of proliferation. Dimensionality reduction showed that injury resulted in a gradient of VSMC phenotypes from contractile to proliferative, with no evidence of a distinct response by a dedicated progenitor population. To characterise this gradual phenotypic change, we performed trajectory analysis, where cells are ordered in 'pseudotime' based on gene expression similarity. Trajectory inference identified two injury response paths of which only one was associated with the transition to active cell proliferation, alongside extracellular matrix organization, and cell adhesion. The second path was enriched for genes associated with protein refolding.